FDA staff backs injection to reduce double chin

(Reuters) - An injection for "double chin" reduction developed by Kythera Biopharmaceuticals Inc cleared the first hurdle toward approval as U.S. Food and Drug Administration staff concluded the drug's benefits outweighed its risks.